Acutus Medical, Inc.
AFIB Healthcare Medical Devices
In the quarter to December 2024, revenue grew 204.2%, EPS grew 95.9% and free cash flow grew 76.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow AFIB
Acutus Medical, Inc. (AFIB) EV/Sales
As of 15 October 2026, Acutus Medical, Inc. (AFIB) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from −38.6× (April 2023) to 60.6× (December 2020); the current reading is higher than 49% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 1.0× | (35.44%) |
| FY2023 | 1.6× | — |
| FY2022 | −0.6× | — |
| FY2021 | 2.2× | (92.23%) |
| FY2020 | 28.0× | 289.79% |
| FY2019 | 7.2× | 0.00% |
| FY2018 | 7.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 1.0× | (29.99%) |
| Sep 2024 | 1.4× | (11.28%) |
| Jun 2024 | 1.6× | (22.52%) |
| Mar 2024 | 2.1× | 34.16% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| DYNTQ Dynatronics Corporation compare | 0.1× |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| BIOLQ Biolase, Inc. compare | 0.3× |
| AFIB Acutus Medical, Inc. | 0.9× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| NXL Nexalin Technology, Inc. compare | 3.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)